EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Effectiveness and Safety of Treatments for Early‐Stage Merkel Cell Carcinoma: A Systematic Review and Meta‐Analysis of Randomized and Non‐Randomized Studies

Yves Paul Vincent Mbous iD, Rowida Mohamed iD, Usha Sambamoorthi iD, Murtuza Bharmal, Khalid M Kamal iD, Traci LeMasters, Joanna Kolodney, George A Kelley iD

Cancer Medicine · 2025-01 · 14 (1)

DOI: 10.1002/cam4.70553 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Medicine, online erschienen am 03.01.2025. Verfasst von Yves Paul Vincent Mbous und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Department of Pharmaceutical Systems and Policy, Robert C. Byrd Health Sciences Center [North], West Virginia University, Morgant…. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Randomized Controlled Trials as Topic, Skin Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The lack of consensus on the benefits and harms of standard therapies, including surgery (SRx), radiotherapy (RTx), chemotherapy (CTx), and their combinations among early‐stage MCC, prompted this study.

Methods

A systematic review and meta‐analysis of randomized and non‐randomized studies published between January 01, 1972, and January 31, 2023, and having overall survival (OS), local recurrence (LR), regional recurrence (RR), disease‐specific survival (DSS), and/or disease‐free survival (DFS) as outcomes was conducted using the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed (NCBI), Scopus (ELSEVIER), and Web of Science (CLAVIRATE) databases. Hazard ratios (HRs) and their variances were pooled using the inverse variance heterogeneity model.

Results

Forty‐nine studies representing 46,215 participants were included in the meta‐analysis. A statistically significant improvement in OS was observed for groups administered adjuvant RTx (SRx + RTx) compared to SRx only (HR = 0.78, 95% CI, 0.62–0.99), albeit with statistically significant heterogeneity ( Q = 532.30, p < 0.001) and a large amount of inconsistency ( I 2 = 94%, 95% CI, 93.0–95.5). Both LR (HR = 1.52, 95% CI, 0.37–6.19) and RR (HR = 0.41, 95% CI, 0.09–1.78) were not statistically significant. In addition, DSS (HR = 0.58, 95% CI, 0.24–1.40) was not statistically significant but DFS was (HR = 0.35, 95% CI, 0.13–0.93). Subgroup analyses revealed that adjuvant radiotherapy was more effective in local than regional MCC. The E‐value suggested that the RTx dose was a confounder of the observed effectiveness of adjuvant RTx; and also, the use of CTx following adjuvant RTx, did not impact the strength of evidence for OS.

Conclusions

Although adjuvant RTx improves survival and recurrence outcomes among early‐stage MCC, the safety and effectiveness of standard therapies in MCC remains poorly studied and, thus, affects the synthesis of evidence across important patient and clinical characteristics. Future research on the comparative effectiveness of different therapies is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellRandomized Controlled Trials as TopicSkin NeoplasmsHumansNeoplasm StagingNeoplasm Recurrence, LocalTreatment OutcomeCombined Modality TherapyDisease-Free SurvivalRadiotherapy, AdjuvantChemotherapy, Adjuvant

Stichwörter der Autor:innen

Merkel cell carcinomadisease‐free survivaldisease‐specific survivallocal recurrencemeta‐analysisoverall survivalregional recurrence

Autor:innen und Institutionen

  • School of Pharmacy, Department of Pharmaceutical Systems and Policy, Robert C. Byrd Health Sciences Center [North], West Virginia University, Morgantown, West Virginia, USA.
  • Department of Obstetrics and Gynecology, Biological Sciences Division, The University of Chicago, Chicago, Illinois, USA.
  • College of Pharmacy, Department of Pharmacotherapy, University of North Texas Health Science Center, Fort Worth, Texas, USA.
  • AstraZeneca Oncology Outcomes Research, Boston, Massachusetts, USA.
  • OPEN Health, Bethesda, Maryland, USA.
  • Department of Hematology/Oncology, School of Medicine, Robert C. Byrd Health Sciences Center [North], West Virginia University, Morgantown, West Virginia, USA.

ORCID-Profile: Yves Paul Vincent Mbous, Rowida Mohamed, Usha Sambamoorthi, Khalid M Kamal, George A Kelley

Zitieren

APA

Mbous, Y. P. V., Mohamed, R., Sambamoorthi, U., Bharmal, M., Kamal, K. M., LeMasters, T., Kolodney, J., & Kelley, G. A. (2025). Effectiveness and Safety of Treatments for Early‐Stage Merkel Cell Carcinoma: A Systematic Review and Meta‐Analysis of Randomized and Non‐Randomized Studies. Cancer Medicine, 14(1). https://doi.org/10.1002/cam4.70553

Vancouver

Mbous YPV, Mohamed R, Sambamoorthi U, Bharmal M, Kamal KM, LeMasters T, et al. Effectiveness and Safety of Treatments for Early‐Stage Merkel Cell Carcinoma: A Systematic Review and Meta‐Analysis of Randomized and Non‐Randomized Studies. Cancer Medicine. 2025;14(1). doi:10.1002/cam4.70553

BibTeX
@article{Mbous2025,
  author = {Mbous, Yves Paul Vincent and Mohamed, Rowida and Sambamoorthi, Usha and Bharmal, Murtuza and Kamal, Khalid M and LeMasters, Traci and Kolodney, Joanna and Kelley, George A},
  title = {Effectiveness and Safety of Treatments for Early‐Stage Merkel Cell Carcinoma: A Systematic Review and Meta‐Analysis of Randomized and Non‐Randomized Studies},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {1},
  doi = {10.1002/cam4.70553}
}
Kostenlos starten →